Birmingham Capital Management Co. Inc. AL Decreases Position in Johnson & Johnson $JNJ

Key Points

• Birmingham Capital Management Co. Inc. AL reduced its stake in Johnson & Johnson by 5.2%, selling 2,130 shares during the first quarter, resulting in holdings worth $6,431,000.
• The company recently posted earnings of $2.77 per share, surpassing consensus estimates, with revenue increasing by 5.8% year-over-year to $23.74 billion.
• Johnson & Johnson announced a quarterly dividend of $1.30 per share, reflecting a dividend yield of 3.0% and a payout ratio of 55.61%.

Birmingham Capital Management Co. Inc. AL trimmed its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 5.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 38,777 shares of the company's stock after selling 2,130 shares during the period. Johnson & Johnson accounts for 2.4% of Birmingham Capital Management Co. Inc. AL's holdings, making the stock its 11th biggest position. Birmingham Capital Management Co. Inc. AL's holdings in Johnson & Johnson were worth $6,431,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of the stock. Elios Financial Group Inc. increased its stake in Johnson & Johnson by 1.5% during the 1st quarter. Elios Financial Group Inc. now owns 4,496 shares of the company's stock worth $746,000 after buying an additional 66 shares in the last quarter. Atlantic Family Wealth LLC boosted its stake in shares of Johnson & Johnson by 4.4% in the first quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company's stock worth $266,000 after acquiring an additional 67 shares during the last quarter. MBA Advisors LLC raised its stake in Johnson & Johnson by 1.2% in the 1st quarter. MBA Advisors LLC now owns 5,553 shares of the company's stock valued at $921,000 after purchasing an additional 68 shares during the last quarter. Sovereign Financial Group Inc. lifted its holdings in Johnson & Johnson by 1.8% in the 1st quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company's stock valued at $651,000 after purchasing an additional 69 shares in the last quarter. Finally, Nabity Jensen Investment Management Inc boosted its stake in Johnson & Johnson by 1.5% during the 1st quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company's stock worth $767,000 after purchasing an additional 69 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Trading Down 0.2%

NYSE JNJ traded down $0.40 during trading hours on Friday, reaching $178.10. The company had a trading volume of 7,220,047 shares, compared to its average volume of 7,548,205. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $428.93 billion, a P/E ratio of 19.05, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40. The stock has a 50-day moving average of $170.81 and a 200 day moving average of $161.30. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same quarter in the previous year, the company earned $2.82 earnings per share. The firm's quarterly revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were paid a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.9%. Johnson & Johnson's dividend payout ratio is presently 55.61%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares of the company's stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.16% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have recently commented on JNJ shares. Citigroup increased their target price on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a "buy" rating in a research report on Thursday, August 21st. Guggenheim reaffirmed a "neutral" rating and set a $167.00 price objective (up previously from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Erste Group Bank raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Wednesday, July 23rd. UBS Group upped their price target on Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a research report on Thursday, July 17th. Finally, Bank of America boosted their price objective on Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a research note on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $176.29.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.